RayKnowChina Research Map
Shortlist0

ChengduUniversity of Electronic Science and Technology of China

Sichuan Cancer Hospital

四川省肿瘤医院

Listed for 8 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Sichuan Cancer Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌25 papers led2 open trials led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌50 papers led1 open trial led
  3. Hepatocellular carcinoma肝细胞癌19 papers led1 open trial led
  4. Stomach cancer胃癌13 papers led
  5. Osteosarcoma骨肉瘤0 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤3 papers led
  7. Neuroblastoma神经母细胞瘤1 paper led
  8. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 25 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
25
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
8
led by another institution
Papers led per year
2021: 3320212022: 4420222023: 6620232024: 3320242025: 992025

5 hospitals in Chengdu for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Nituzumab (Taixinsheng ®) A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2022-04
    Registry
    NCT05508347

    Age 18 years to 70 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  2. Not yet recruiting
    A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2025-07
    Registry
    NCT07062484

    Age 18 years to Not stated (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  3. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  4. Recruiting
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06839066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan

  5. Recruiting
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Registry
    NCT07258979

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Jiangmen, Kunming, Nanchang, Nanning, Shanghai, Shaoguan, Xiamen

  6. Recruiting
    Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07303023

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Chongqing, Hangzhou, Shanghai

  7. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

  8. Recruiting
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06308328

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai

  9. Recruiting
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05340491

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  10. Recruiting
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    Phase
    Phase 3
    Started
    2020-03
    Registry
    NCT03907826

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseImaging & AI
Departments in papersRadiation oncologyRadiology / nuclear medicinePathology / laboratory medicineGastroenterology / hepatology
Papers it led25
  1. Efficacy of radiotherapy in treating local recurrence concomitant with distant metastasis of nasopharyngeal carcinoma: a long-term retrospective multicenter study.2025Clinical & experimental metastasis
  2. Short-course PD-1 blockade in locally advanced nasopharyngeal carcinoma: a phase II randomized trial protocol (Tori-013).2025Frontiers in immunologyFree full text
  3. The Effect of Rabdosia rubescens on Radiotherapy-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients: A Phase II Clinical Study.2025Integrative cancer therapiesFree full text
  4. Generalizable Magnetic Resonance Imaging-based Nasopharyngeal Carcinoma Delineation: Bridging Gaps Across Multiple Centers and Raters With Active Learning.2025International journal of radiation oncology, biology, physics
  5. Deformable dose prediction network based on hybrid 2D and 3D convolution for nasopharyngeal carcinoma radiotherapy.2025Medical & biological engineering & computing
  6. SegRap2023: A benchmark of organs-at-risk and gross tumor volume Segmentation for Radiotherapy Planning of Nasopharyngeal Carcinoma.2025Medical image analysis
  7. Early prediction of parotid glands secretory function based on ADC variations during radiotherapy for nasopharyngeal carcinoma: a phase II prospective study.2025Radiation oncology (London, England)Free full text
  8. MB based RT-qPCR increase the clinical application of cfEBV DNA for NPC in non-endemic area of China.2025Scientific reportsFree full text
  9. Correlation between taste and smell alterations and quality of life in patients treated with radiotherapy for nasopharyngeal carcinoma: a cross-sectional study in China.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  10. Risk stratification of LA-NPC during chemoradiotherapy based on clinical classification and TVRR.2024Cancer medicineFree full text
  11. A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma.2024Oral oncology
  12. A multicenter dataset for lymph node clinical target volume delineation of nasopharyngeal carcinoma.2024Scientific dataFree full text
  13. Intra- and peritumoral MRI radiomics assisted in predicting radiochemotherapy response in metastatic cervical lymph nodes of nasopharyngeal cancer.2023BMC medical imagingFree full text
  14. Efficacy and safety of PLDR-IMRT for the re-irradiation of recurrent NPC: A prospective, single-arm, multicenter trial.2023Cancer scienceFree full text
  15. Clinical relevance of plasma EBV DNA as a biomarker for nasopharyngeal carcinoma in non-endemic areas: A multicenter study in southwestern China.2023Clinica chimica acta; international journal of clinical chemistry
  16. Radiomic analysis of MRI for prediction of response to induction chemotherapy in nasopharyngeal carcinoma patients.2023Clinical radiology
  17. Endoscopic ultrasound-guided fine-needle aspiration to diagnose a recurrent nasopharyngeal carcinoma in the parapharyngeal space.2023EndoscopyFree full text
  18. A promising predictive biomarker combined EBV NDA with PNI for nasopharyngeal carcinoma in nonendemic area of China.2023Scientific reportsFree full text
  19. Dosimetric analysis of radiation-induced brainstem necrosis for nasopharyngeal carcinoma treated with IMRT.2022BMC cancerFree full text
  20. Evaluation of the efficacy of the anti-ulcer oral mucosal protective agent RADoralex® in the prevention and treatment of radiation-induced oral mucosal reactions induced during treatment of nasopharyngeal carcinoma.2022Cancer biology & therapyRCTFree full text
  21. Lymph drainage and cervical fascia anatomy-oriented differential nodal CTV delineation at the supraclavicular region for esophageal cancer and nasopharyngeal cancer.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  22. Level Ib CTV delineation in nasopharyngeal carcinoma based on lymph node distribution and topographic anatomy.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  23. Single nucleotide polymorphisms within NFKBIA are associated with nasopharyngeal carcinoma susceptibility in Chinese Han population.2021Cytokine
  24. A novel technique of endonasopharyngeal ultrasound-guided transnasopharyngeal needle aspiration in the diagnosis of submucosal recurrence of nasopharyngeal carcinoma after chemoradiotherapy.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  25. MRI-based radiomics as response predictor to radiochemotherapy for metastatic cervical lymph node in nasopharyngeal carcinoma.2021The British journal of radiologyFree full text
All its trials on ClinicalTrials.gov, any status20
  1. A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07062484Lead sponsorN/AStart 2025-07
  2. Nituzumab (Taixinsheng ®) A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT05508347Lead sponsorPhase 2Start 2022-04
  3. Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal CarcinomaCompletedNCT05292027Lead sponsorN/AStart 2022-03
  4. Low-dose Radiotherapy and Neoadjuvant Chemotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal CarcinomaStatus unknownNCT05503914Lead sponsorN/AStart 2022-08
  5. PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II TrialStatus unknownNCT05520814Lead sponsorPhase 2Start 2018-08
  6. Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal CarcinomaCompletedNCT03180476Lead sponsorPhase 2Start 2017-04
  7. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  8. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.RecruitingNCT07258979Study sitePhase 1/Phase 2Start 2025-11
  9. Individualized Neck Cervical Irradiation Prophylaxis Trial of NPCRecruitingNCT07303023Study sitePhase 3Start 2025-09
  10. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Study sitePhase 2Start 2025-04
  11. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  12. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT06308328Study siteStart 2024-04
  13. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Study sitePhase 3Start 2022-04
  14. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Study sitePhase 3Start 2020-03
  15. Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT06712888Study sitePhase 3Start 2025-02
  16. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  17. The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNCCompletedNCT04929080Study sitePhase 1/Phase 2Start 2021-05
  18. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  19. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
  20. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02633176Study sitePhase 3Start 2015-01
More papers found outside PubMed (not counted)40
  1. A Randomized, Controlled, Single-Blind, Multicenter Phase II/III Clinical Trial of PD-1 Inhibitor Combined with Chemoradiotherapy for the Treatment of T1-2N2-3/T3-4N0-3M0 Stage Nasopharyngeal Carcinoma — Study Protocol2025International Journal of Radiation Oncology*Biology*Physicsarticle
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  3. Assessment Tools for Health‐Related Quality of Life in Patients With Nasopharyngeal Carcinoma: A Systematic Review of Psychometric Properties2025European Journal of Cancer Carereview
  4. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.2025Journal of Clinical Oncologyarticle
  5. Bioinformatics analysis of immune‐programmed cell death‐related genes in nasopharyngeal carcinoma2025Eye & ENT Researcharticle
  6. Impact of Offline Adaptive Radiotherapy on Survival and Quality of Life in Locally Advanced Nasopharyngeal Carcinoma: A Propensity-Matched Retrospective Study2025Research Squarepreprint
  7. Research on the Application of Raman Spectroscopy in Predicting the Efficacy of Nasopharyngeal Carcinoma Treatment and Assessing Acute Adverse Reactions to Radiotherapy2025International Journal of Radiation Oncology*Biology*Physicsarticle
  8. Systematic review of the effects and safety of toripalimab combined with chemotherapy on the immune level in patients with nasopharyngeal carcinoma2025Asian Journal of Surgeryreview
  9. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncologyconference-abstract
  10. WITHDRAWN: 1440TiP Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine(GX) versus tislelizumab plus gemcitabine/cisplatin(GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multic2025Annals of Oncologyretraction
  11. 92P An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population2024Immuno-Oncology Technologyarticle
  12. Dataset, Challenge, and Evaluation for Tumor Segmentation Variability2024ACM International Conference on Multimedia (ACM MM)conference-paper
  13. Domain composition and attention network trained with synthesized unlabeled images for generalizable medical image segmentation2024Neurocomputingarticle
  14. Multi-Sequence MRI Based Metachronous Single-Organ Metastasis Prediction of Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  15. Multimodal Magnetic Resonance-Based Clinicoradiomics for Predicting Suspicious Lymph Node Metastasis in Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  16. RPL-SFDA: Reliable Pseudo Label-Guided Source-Free Cross-Modality Adaptation for NPC GTV Segmentation2024IEEE International Symposium on Biomedical Imaging (ISBI)conference-paper
  17. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncologyarticle
  18. Long-Term Outcomes of Stereotactic Body Radiation Therapy with or without PD-1 Inhibitors in Metastatic Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  19. Long-Term Survival Outcome for Metastatic Nasopharyngeal Carcinoma Patients Receiving Radiation to Primary and Metastatic Sites with Palliative Chemotherapy2023International Journal of Radiation Oncology*Biology*Physicsarticle
  20. Low-Dose Fractionated Radiotherapy Combined with Neoadjuvant Chemotherapy for T3-4 Nasopharyngeal Carcinoma Patients: The Preliminary Results of a Phase II Randomized Controlled Trial2023International Journal of Radiation Oncology*Biology*Physicsarticle
  21. Low-dose fractionated radiotherapy combined with neoadjuvant chemotherapy for T3-4 nasopharyngeal carcinoma patients: Preliminary results of a phase II randomized controlled trial.2023Journal of Clinical Oncologyconference-abstract
  22. Research on Longitudinal change trends and influencing factors of eating behaviour in patients with nasopharyngeal carcinoma undergoing radiotherapy2023Research Squarepreprint
  23. Visible lymph node irradiation (VNRT) of the low-risk neck levels inpatients with nasopharyngeal carcinoma: An exploratory trial protocol2023Research Squarepreprint
  24. 236P Chrono-chemotherapy combined with radiotherapy for locally advanced nasopharyngeal carcinoma: A meta-analysis2022Annals of Oncologyarticle
  25. Comprehensive treatment of recurrent and metastatic nasopharyngeal carcinoma: advances and future directions2022Precision Radiation Oncologyarticle
  26. Early Prediction Model of Radiation-Induced Xerostomia Based on Radiomics during Radiotherapy for Nasopharyngeal Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  27. Establishment and verification of a radiomics nomogram to predict distant metastasis in patients with descending type of nasopharyngeal carcinoma2022MedComm – Oncologyarticle
  28. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncologyconference-abstract
  29. Preliminary Analysis of Concurrent Programmed Cell Death-1 Inhibitor Combination with Chemoradiation for Recurrent/Metastatic Nasopharyngeal Carcinoma Patients: A Phase II Study2022International Journal of Radiation Oncology*Biology*Physicsarticle
  30. 873P Early efficacy prediction of nasopharyngeal carcinoma based on 3D-ADC acquired during radiotherapy: A phase II prospective study2021Annals of Oncologyarticle
  31. Automatic segmentation of organs-at-risk from head-and-neck CT using separable convolutional neural network with hard-region-weighted loss2021Neurocomputingarticle
  32. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncologyconference-abstract
  33. Correlation Between Immune Function Status and EBV DNA in Patients with Nasopharyngeal Carcinoma and Their Influence on Prognosis2021DOAJ (DOAJ: Directory of Open Access Journals)article
  34. Dilated Adversarial U-Net Network for automatic gross tumor volume segmentation of nasopharyngeal carcinoma2021Applied Soft Computingarticle
  35. Early Efficacy Prediction of Nasopharyngeal Carcinoma Based on 3D-ADC Acquired During Radiotherapy: A Phase II Prospective Study2021International Journal of Radiation Oncology*Biology*Physicsarticle
  36. Early efficacy prediction of nasopharyngeal carcinoma based on 3D-ADC value acquired during radiotherapy: A phase II prospective study.2021Journal of Clinical Oncologyconference-abstract
  37. Efficient Semi-supervised Gross Target Volume of Nasopharyngeal Carcinoma Segmentation via Uncertainty Rectified Pyramid Consistency2021Lecture notes in computer scienceconference-paper
  38. Low-Dose Ultra-Fractionated Radiotherapy as a Chemosensitizer of Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma: A Preliminary Results of the Phase II Trial2021International Journal of Radiation Oncology*Biology*Physicsarticle
  39. Low-dose ultra-fractionated radiotherapy as a chemosensitizer of neoadjuvant chemotherapy for locally advanced nasopharyngeal carcinoma: A preliminary results of the phase II trial.2021Journal of Clinical Oncologyconference-abstract
  40. Predictive Value of Ki-67 for Neoadjuvant Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 50 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 1.7%.

Papers led
50
2021–2025
Trials led
17
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 6620212022: 7720222023: 8820232024: 161620242025: 13132025

3 hospitals in Chengdu for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05244798

    Age 18 years to 75 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  2. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  3. Recruiting
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07733830

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou

  4. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentSurgeryRadiotherapy
Departments in papersRadiation oncologyPathology / laboratory medicineRadiology / nuclear medicine
Papers it led50
  1. Prognostic Impact of Sarcopenia and Surgical Timing in Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoradiotherapy: TIMES Study.2025Annals of surgical oncology
  2. Enhanced prognosis prediction model in esophageal cancer via lymph node assessment post-neoadjuvant.2025BMC cancerFree full text
  3. Comparative analysis and optimization of tumor regression grade assessment systems in neoadjuvant therapy for esophageal squamous cell carcinoma.2025BMC cancerFree full text
  4. Impact of occupation on survival of esophageal squamous cell carcinoma patients following esophagectomy: a long-term survival analysis.2025BMC gastroenterologyFree full text
  5. Real-world efficacy of PD-1 inhibitors in treating oesophageal squamous cell carcinoma (ESCAPE): protocol of a multicentre, real-world, observational, cohort study.2025BMJ openFree full text
  6. Neoadjuvant chemotherapy or chemoradiotherapy plus sintilimab versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a study protocol of a multicentre, randomised, controlled, phase III trial (SCIENCE2025BMJ openFree full text
  7. Involved-Field Irradiation Versus Elective Nodal Irradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy.2025Cancer medicineFree full text
  8. CBX6 induces CD8+ T cell exhaustion and tumor development in esophageal squamous cell carcinoma through SMARCD1-mediated CCL8 secretion and lactate efflux.2025Cell biology and toxicologyFree full text
  9. Long-term outcomes of minimally invasive esophagectomy vs. open esophagectomy in older patients with esophageal squamous cell carcinoma: a propensity score matching analysis.2025Langenbeck's archives of surgeryFree full text
  10. Predictive value of myosteatosis and subcutaneous adipose tissue on the prognosis of ESCC patients undergoing chemoradiotherapy.2025Scientific reportsFree full text
  11. Fluorescence quantitative assessment of blood perfusion in the gastric conduit to reduce anastomotic leakage after esophagectomy: a randomized controlled trial.2025Surgical endoscopyRCT
  12. Long-term outcomes of intrathoracic versus cervical anastomosis after esophagectomy: A large-scale propensity score matching analysis.2025The Journal of thoracic and cardiovascular surgery
  13. Lymph node ratio predicts adjuvant chemotherapy benefit in esophageal squamous cell carcinoma.2025The oncologistFree full text
  14. ASO Author Reflections: Impact of Metastatic Lymph Nodes on Survival of Patients with pN1-Category Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  15. Impact of Metastatic Lymph Nodes on Survival of Patients with pN1-Category Esophageal Squamous Cell Carcinoma: A Long-Term Survival Analysis.2024Annals of surgical oncologyFree full text
  16. Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer after Neoadjuvant Chemoradiotherapy: A Retrospective Study.2024Annals of surgical oncology
  17. Development and Validation of a Recurrence-Free Survival Prediction Model for Locally Advanced Esophageal Squamous Cell Carcinoma with Neoadjuvant Chemoradiotherapy.2024Annals of surgical oncologyFree full text
  18. Comparison of pathologic response and survival outcomes between neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant immunochemotherapy (nICT) in patients with locally advanced esophageal squamous cell carcinoma: a propensity score-matched 2024BMC cancerFree full text
  19. Reduction in chemotherapy relative dose intensity decreases overall survival of neoadjuvant chemoradiotherapy in patients with locally advanced esophageal carcinoma.2024BMC cancerFree full text
  20. Prognostic value of sarcopenia and inflammatory indices synergy in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy.2024BMC cancerFree full text
  21. Long-term outcomes of smoker and drinker with oesophageal squamous cell carcinoma after oesophagectomy: a large-scale propensity score matching analysis.2024BMJ open gastroenterologyFree full text
  22. Computed tomography-based radiomics nomogram for prediction of lympho-vascular and perineural invasion in esophageal squamous cell cancer patients: a retrospective cohort study.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  23. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.2024Frontiers in immunologyFree full text
  24. Resected lymph nodes and survival of patients with esophageal squamous cell carcinoma in pT2 and pT3.2024International journal of surgery (London, England)Free full text
  25. Surgical vs nonsurgical treatment for esophageal squamous cell carcinoma in patients older than 70 years: a propensity score matching analysis.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  26. Prognostic significance of positive lymph node regression grade to neoadjuvant chemoradiation for esophageal squamous cell carcinoma.2024Journal of surgical oncology
  27. Toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial.2024Nature communicationsFree full text
  28. Prognostic value of sarcopenia and myosteatosis alterations on survival outcomes for esophageal squamous cell carcinoma before and after radiotherapy.2024Nutrition (Burbank, Los Angeles County, Calif.)
  29. Longitudinal patient-reported outcomes after minimally invasive McKeown esophagectomy for patients with esophageal squamous cell carcinoma.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  30. ASO Author Reflections: Using Efficacy Index to Clarify the Clinical Value of Each Lymph Node Station for Esophageal Squamous Cell Carcinoma.2023Annals of surgical oncology
  31. Mapping of Lymph Node Metastasis and Efficacy Index in Thoracic Esophageal Squamous Cell Carcinoma: A Large-Scale Retrospective Analysis.2023Annals of surgical oncology
  32. Clinical value of folate receptor-positive circulating tumor cells in patients with esophageal squamous cell carcinomas: a retrospective study.2023BMC cancerFree full text
  33. A prognostic nomogram that includes MPV in esophageal squamous cell carcinoma.2023Cancer medicineFree full text
  34. Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma.2023Frontiers in immunologyFree full text
  35. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.2023Frontiers in immunologyFree full text
  36. Resected lymph nodes and survival of patients with esophageal squamous cell carcinoma: an observational study.2023International journal of surgery (London, England)Free full text
  37. Machine learning‑based prediction of survival prognosis in esophageal squamous cell carcinoma.2023Scientific reportsFree full text
  38. Letter to the editor regarding"STAT3β disrupted mitochondrial electron transport chain enhances chemosensitivity by inducing pyroptosis in esophageal squamous cell carcinoma".2022Cancer letters
  39. Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials.2022Frontiers in immunologyFree full text
  40. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.2022Frontiers in immunologyFree full text
  41. Alleviation of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma and its relationship with expression and changes of PD-L1.2022Neoplasma
  42. Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.2022Radiation oncology (London, England)Free full text
  43. Profiling patient-reported symptom recovery from oesophagectomy for patients with oesophageal squamous cell carcinoma: a real-world longitudinal study.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  44. Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.2022The oncologistFree full text
  45. ASO Author Reflections: Prognostic Role of a Coagulation Index for Patients with Esophageal Squamous Cell Cancer.2021Annals of surgical oncology
  46. Downregulation of lncRNA LINC-PINT Participates in the Recurrence of Esophageal Squamous Cell Carcinoma Possibly by Interacting miRNA-21.2021Cancer biotherapy & radiopharmaceuticals
  47. Clinical utility of the systemic immune-inflammation index for predicting survival in esophageal squamous cell carcinoma after radical radiotherapy.2021Future oncology (London, England)
  48. Clinical Application Value of the Prognostic Nutritional Index for Predicting Survival in Patients with Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy or Radiotherapy.2021Nutrition and cancer
  49. Identification of tumor-infiltrating lymphocyte subpopulations correlated with patient prognosis in esophageal squamous cell carcinoma.2021The Journal of international medical researchFree full text
  50. Unresected small lymph node assessment predicts prognosis for patients with pT3N0M0 thoracic esophageal squamous cell carcinoma.2021World journal of surgical oncologyFree full text
All its trials on ClinicalTrials.gov, any status29
  1. Sintilimab Plus NCT or NCRT Versus NCRT for ESCCNot yet recruitingNCT05244798Lead sponsorPhase 3Start 2022-11
  2. Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCCActive, not recruitingNCT05189730Lead sponsorPhase 2Start 2021-07
  3. Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest.Status unknownNCT05044728Lead sponsorPhase 2Start 2021-04
  4. Surveillance of Peripheral Blood of Lymphocyte and Immunocyte in Neoadjuvant Therapy Patients With Esophageal Squamous Cell Carcinoma (pLINE)Status unknownNCT04440332Lead sponsorStart 2020-07
  5. Quantitative Assessment of Blood Supply in the Gastic Conduit With Fluorescence Angiography for Esophageal ReconstructionStatus unknownNCT04229524Lead sponsorN/AStart 2020-06
  6. Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04177797Lead sponsorPhase 2Start 2020-03
  7. Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04602013Lead sponsorPhase 2Start 2020-10
  8. Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT02123381Lead sponsorPhase 2Start 2014-04
  9. Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal CarcinomaCompletedNCT02399306Lead sponsorPhase 3Start 2014-09
  10. Outcomes of Smoker and Drinker With Esophageal Squamous Cell Carcinoma After EsophagectomyStatus unknownNCT06269341Lead sponsorStart 2010-02
  11. Effect of Cervical Paraesophageal Lymph Node Metastasis Versus Supraclavicular Lymph Node Metastasis on the Overall Survival of Patients With Thoracic Esophageal Squamous Cell Carcinoma: An Observational StudyCompletedNCT06165094Lead sponsorStart 2009-01
  12. Development and Validation of a Survival Prediction Model for Esophageal Cancer Patients After EsophagectomyCompletedNCT06169930Lead (inferred)Start 2023-12
  13. Clinical Value and Efficacy Index of Lymphadenectomy for Thoracic EsccCompletedNCT05604664Lead (inferred)Start 2022-05
  14. The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: An Observational StudyCompletedNCT05617352Lead (inferred)Start 2022-05
  15. RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDYStatus unknownNCT05570487Lead (inferred)Start 2022-10
  16. Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCCCompletedNCT06775652Lead (inferred)Phase 3Start 2018-01
  17. Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCCCompletedNCT07236320Lead (inferred)N/AStart 2018-03
  18. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Study sitePhase 2Start 2026-07
  19. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  20. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  21. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  22. A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCCStatus unknownNCT05221658Study sitePhase 2Start 2022-08
  23. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  24. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  25. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  26. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  27. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)CompletedNCT04210115Study sitePhase 3Start 2020-02
  28. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  29. Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.CompletedNCT06190652Study siteStart 2018-10
More papers found outside PubMed (not counted)74
  1. 251. PRELIMINARY SURGICAL OUTCOMES FROM MULTICENTER, RANDOMIZED PHASE III TRIAL (SCIENCE): IMPACT OF NEOADJUVANT SINTILIMAB-BASED REGIMENS ON RESECTABLE LOCALLY ADVANCED ESCC2025Diseases of the Esophagusarticle
  2. 253. MICROBIOTA ENTEROTOXIGENIC BACTEROIDES FRAGILIS (ETBF) PROMOTES ESCC TUMOR FORMATION, MIGRATION, AND INVASION BY PROMOTING EMT AND ACTIVATING TLR4/NF-κB SIGNALING PATHWAY2025Diseases of the Esophagusarticle
  3. 273. LONG-TERM SURVIVAL AND TREATMENT PATTERNS IN RESECTABLE ESCC IN EAST ASIA: A COMPREHENSIVE STUDY FROM THE INTERNATIONAL ESODATA-STUDY-GROUP (DRAGON STUDY)2025Diseases of the Esophagusarticle
  4. 293. LONG-TERM OUTCOMES OF MINIMALLY INVASIVE ESOPHAGECTOMY VS. OPEN ESOPHAGECTOMY IN ELDERLY: A PROPENSITY SCORE MATCHING ANALYSIS2025Diseases of the Esophagusarticle
  5. 296. IMPACT OF SEASONS ON ELDERLY PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOLLOWING ESOPHAGECTOMY: A PROPENSITY SCORE MATCHING ANALYSIS2025Diseases of the Esophagusarticle
  6. 297. COMPARING SURVIVAL AND COMPLICATION RATES IN CERVICAL VS. INTRATHORACIC ANASTOMOSIS FOR ELDERLY ESOPHAGEAL CANCER PATIENTS2025Diseases of the Esophagusarticle
  7. 299. SEX-BASED ANALYSIS OF CLINICAL OUTCOMES IN ELDERLY PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA POST-ESOPHAGECTOMY: A PROPENSITY SCORE MATCHING ANALYSIS2025Diseases of the Esophagusarticle
  8. 300. IMPACT OF OCCUPATION ON SURVIVAL OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS FOLLOWING ESOPHAGECTOMY: A LONG-TERM SURVIVAL ANALYSIS2025Diseases of the Esophagusarticle
  9. 395. IMPACT OF PREOPERATIVE COMORBIDITIES ON ELDERLY PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOLLOWING ESOPHAGECTOMY: A PROPENSITY SCORE MATCHING ANALYSIS2025Diseases of the Esophagusarticle
  10. 486eTiP Interim results and ctDNA biomarker analysis from the phase III SCIENCE trial: Neoadjuvant chemotherapy or chemoradiotherapy with/without sintilimab for resectable locally advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  11. 486eTiP Interim results and ctDNA biomarker analysis from the phase III SCIENCE trial: Neoadjuvant chemotherapy or chemoradiotherapy with/without sintilimab for resectable locally advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  12. A Longitudinal CT-Based Subregional Radiomics Nomogram for Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy: A Multicenter Study2025International Journal of Radiation Oncology*Biology*Physicsarticle
  13. A Multi-Dimensional Deep Ensemble Learning Model Predicts Pathological Response and Treatment Outcomes to Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Using Pretreatment CT Images: A Multicenter, Retrospective Cohort 2025International Journal of Radiation Oncology*Biology*Physicsarticle
  14. DRNP-G4: a CRISPR-based dual-mode biosensor for amplification-free and ultrasensitive detection of miRNA-212025Microchemical Journalarticle
  15. Impact of Muscle Mass Loss on Survival during Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center Retrospective Study in China (TIMES Study)2025International Journal of Radiation Oncology*Biology*Physicsarticle
  16. Impact of muscle mass loss on survival during neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma: A multi-center retrospective study in China (TIMES study).2025Journal of Clinical Oncologyarticle
  17. Long-term outcomes of toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: Results from a phase II trial.2025Journal of Clinical Oncologyarticle
  18. Preliminary results from the multicenter, randomized phase III trial (SCIENCE): Comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced e2025Journal of Clinical Oncologyarticle
  19. Prognostic impact of sarcopenia and surgical timing in locally advanced esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy: TIMES study.2025Journal of Clinical Oncologyarticle
  20. Real-world effectiveness and safety of first-line serplulimab in patients with metastatic or locally advanced esophageal carcinoma.2025Journal of Clinical Oncologyarticle
  21. Sequential Chemo-Immunotherapy as a Novel Bridging Strategy for Non-Complete Responders after Neoadjuvant Chemoradiotherapy in Esophageal Cancer: First Prospective Phase 2 Trial Challenging Immediate Surgery Paradigm2025International Journal of Radiation Oncology*Biology*Physicsarticle
  22. Sequential chemo-immunotherapy as a novel bridging strategy for non-complete responders after neoadjuvant chemoradiotherapy in esophageal cancer: First prospective phase 2 trial challenging the immediate-surgery paradigm.2025Journal of Clinical Oncologyconference-abstract
  23. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  24. Correlation of circulating T lymphocytes with response to neoadjuvant chemoimmunotherapy in operable esophageal squamous cell carcinoma2024Research Squarepreprint
  25. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  26. Longitudinal CT Feature-Based Model for Predicting Local Recurrence Free Survival in Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: A Multicenter Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  27. Multimodality Deep Learning Radiomics Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy2024International Journal of Radiation Oncology*Biology*Physicsarticle
  28. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Squarepreprint
  29. Prognostic Value of Sarcopenia and Inflammatory Indices Synergy in Patients with Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy2024International Journal of Radiation Oncology*Biology*Physicsarticle
  30. Sintilimab Combined with Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Multicenter, Phase 2 Trial2024International Journal of Radiation Oncology*Biology*Physicsarticle
  31. Sintilimab combined with definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: A single-arm, multicenter, phase 2 trial.2024Journal of Clinical Oncologyconference-abstract
  32. The role of folate receptor-positive circulating tumor cells in the prognosis analysis of esophageal squamous cell carcinomas.2024Journal of Clinical Oncologyconference-abstract
  33. Tislelizumab plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients after Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  34. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical t2024Journal of Clinical Oncologyconference-abstract
  35. Toripalimab plus Chemotherapy and Radiotherapy for Treatment-Naive, Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm Phase II Trial2024International Journal of Radiation Oncology*Biology*Physicsarticle
  36. 1529P Tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)2023Annals of Oncologyarticle
  37. 204. CORRELATION OF CIRCULATING T LYMPHOCYTES WITH RESPONSE TO NEOADJUVANT CHEMOIMMUNOTHERAPY IN OPERABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2023Diseases of the Esophagusarticle
  38. 205. LONGITUDINAL PATIENT-REPORTED OUTCOMES AFTER MINIMALLY INVASIVE MCKEOWN ESOPHAGECTOMY IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA2023Diseases of the Esophagusarticle
  39. 227. RELATIONSHIP BETWEEN 90-DAY PROGNOSIS NUTRITIONAL INDEX AND INFLAMMATORY RESPONSE MARKERS AND LONG-TERM SURVIVAL IN ESOPHAGEAL CANCER2023Diseases of the Esophagusarticle
  40. 343. T LYMPHOCYTE SUBSETS CHARACTERISTICS IN DIFFERENT CURATIVE EFFICACY OF NEOADJUVANT THERAPY FOR PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA2023Diseases of the Esophagusarticle
  41. A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma.2023Journal of Clinical Oncologyconference-abstract
  42. Comparison of Pathologic Response and Survival Outcomes between Neoadjuvant Immunochemotherapy (nICT) and Neoadjuvant Chemoradiotherapy (nCRT) in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched 2023International Journal of Radiation Oncology*Biology*Physicsarticle
  43. Endoscopic Ultrasonography-Derived Maximum Tumor Thickness and Tumor Shrinkage Rate as Independent Prognostic Factors in Locally Advanced Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy2023International Journal of Radiation Oncology*Biology*Physicsarticle
  44. Evaluation of Antitumor Immunity by a Combination Treatment of Radiation, Anti-PD1, and Anti-Angiogenic Therapy in Esophageal Squamous Cell Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  45. Long-term Outcomes of Treatment Patterns and Survival for Esophageal Squamous Cell Carcinoma Over than 70 Years: A Multicenter Analysis of 726 Cases2023Research Squarepreprint
  46. Long-term survival of esophageal squamous cell carcinoma after surgical treatment in a large-scale retrospective study from a single cancer center2023Holistic Integrative Oncologyarticle
  47. Peripheral Monocyte Count as an Independent Prognostic Factor for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma2023Journal on Surgeryarticle
  48. Postoperative Survival Effect of Examined Lymph Node Count in Node-Negative Esophageal Carcinoma2023Preprints.orgpreprint
  49. Sintilimab Injection Combination with Concurrent Chemoradiotherapy (cCRT) in Patients with Localized Esophageal Squamous Cell Carcinoma: A Prospective, Multi-Center, Single-Arm Trial in Progress2023International Journal of Radiation Oncology*Biology*Physicsarticle
  50. Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).2023Journal of Clinical Oncologyconference-abstract
  51. 124. LONGITUDINAL STUDY OF POSTOPERATIVE SYMPTOMS AND QUALITY OF LIFE IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  52. 177. TORIPALIMAB COMBINATION WITH CHEMOTHERAPY AND SUBSEQUENT RADIATION IN PATIENTS WITH STAGE IV ESOPHAGEAL CARCINOMA,A PROSPECTIVE PHASE II STUDY (TR-EAT TRIAL)2022Diseases of the Esophagusarticle
  53. 325. THE ASSOCIATED RISK BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS OF AP1S1 AND ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN CHINESE POPULATION2022Diseases of the Esophagusarticle
  54. 362. CLINICAL VALUE AND EFFICACY INDEX OF LYMPHADENECTOMY FOR THORACIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  55. 363. THE MODALITY OF NEOADJUVANT VERSUS ADJUVANT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL. CARCINOMA: A SINGLE CENTER, RANDOMIZED, CLINICAL TRIAL2022Diseases of the Esophagusarticle
  56. 373. STRATEGIES ON OPTIMAL LYMPHADENECTOMY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A RETROSPECTIVE ANALYSIS OF 1517 CASES IN A SINGLE CANCER CENTER2022Diseases of the Esophagusarticle
  57. 376. THE IMPACT OF OVERALL SURVIVAL ON TWO-FIELD OR THREE-FIELD LYMPHADENECTOMY IN MIDDLE AND LOWER THORACIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  58. Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Randomized Phase III Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  59. Phase II Study of Toripalimab in Combination with Induction Chemotherapy and Subsequent Chemo- Radiation in Patients with Advanced/Metastatic Esophageal Carcinoma (TR-EAT Trial)2022International Journal of Radiation Oncology*Biology*Physicsarticle
  60. 177 CT RADIOMICS BASED ON MACHINE LEARNING PREDICTING PATHOLOGIC COMPLETE RESPONSE AFTER NEOADJUVANT CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER2021Diseases of the Esophagusarticle
  61. 413 Toripalimab in combination with concurrent chemoradiation in patients with advanced/metastatic esophageal carcinoma: protocol for a single-arm, prospective, open-label, phase II clinical trial2021Journal for ImmunoTherapy of Cancerconference-abstract
  62. 629 IRRADIATED ESOPHAGEAL SQUAMOUS CELL CARCINOMA CELLS INDUCED THE INCREASE OF TREG BY TGF-β2021Diseases of the Esophagusarticle
  63. 631 CLINICAL APPLICATION VALUE OF THE SYSTEMIC-IMMUNE-INFLAMMATION-INDEX FOR PREDICTING SURVIVAL IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA UNDERGOING CHEMORADIOTHERAPY OR RADIOTHERAPY2021Diseases of the Esophagusarticle
  64. 684 MODERATELY DIFFERENTIATED ESOPHAGEAL SQUAMOUS CELL CARCINOMA HAS A POOR PROGNOSIS AFTER NEOADJUVANT CHEMORADIOTHERAPY2021Diseases of the Esophagusarticle
  65. 685 THE IMPACT OF ADJUVANT THERAPY ON SURVIVAL FOR NODE-NEGATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PROPENSITY SCORE MATCHED ANALYSIS2021Diseases of the Esophagusarticle
  66. 689 MMS22L EXPRESSION AS A PREDICTIVE BIOMARKER FOR THE EFFICACY OF NEOADJUVANT CHEMORADIOTHERAPY IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2021Diseases of the Esophagusarticle
  67. 695 METASTASIS OF THORACIC RECURRENT LARYNGEAL NERVE LYMPH NODE AS PREDICTOR FOR CERVICAL LYMPH NODE DISSECTION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2021Diseases of the Esophagusarticle
  68. Development of a Prognostic Nomogram and Risk Stratification System for Upper Thoracic Esophageal Squamous Cell Carcinoma2021Research Squarepreprint
  69. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  70. Irradiated esophageal squamous cell carcinoma cells induced the increase of Treg by TGF-beta.2021Journal of Clinical Oncologyconference-abstract
  71. Mechanism of Increased Treg Frequency Induced by Irradiated Esophageal Squamous Cell Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle
  72. Primary Gross Tumor Volume is Prognostic and Suggests Treatment in Upper Esophageal Cancer2021Research Squarepreprint
  73. Profiling Patient-Reported Symptom Recovery from Esophagectomy for Patients with Esophageal Squamous Cell Carcinoma: A Real World Longitudinal Study2021Research Squarepreprint
  74. Unresected Small Lymph Nodes Assessment Predict Prognosis For Patients With pT3N0M0 Thoracic Esophageal Squamous Cell Carcinoma2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 19 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
19
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 5520232024: 5520242025: 882025

5 hospitals in Chengdu for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06485466

    Age 18 years to 80 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  2. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  3. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  4. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisLocal treatment (ablation, TACE, HAIC)Immunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineRadiation oncologyGastroenterology / hepatology
Papers it led19
  1. Construction and validation of a novel liver function-tumor burden-inflammation-nutrition (LTIN) score for HCC patients underwent hepatectomy.2025BMC cancerFree full text
  2. Efficacy and safety of postoperative adjuvant HAIC with FOLFOX combining PD-1 inhibitors in HCC patients with microvascular invasion: a propensity score matching analysis.2025BMC cancerFree full text
  3. Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study.2025European journal of radiology
  4. Neoadjuvant therapy with triple therapy for centrally located hepatocellular carcinoma.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  5. Preoperative TACE with PD-1 inhibitors and TKIs in beyond "up-to-seven" hepatocellular carcinoma: a propensity score matched analysis.2025Frontiers in immunologyFree full text
  6. FCGR2A defines prognostic immune subtypes and drives tumor progression in hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  7. Efficacy and safety of postoperative adjuvant HAIC combining lenvatinib with or without PD-1 inhibitors in solitary large HCC: A multicenter retrospective study.2025Frontiers in immunologyFree full text
  8. EMP2 promotes hepatocellular carcinoma proliferation and invasion by activating cellular autophagy.2025Oncology researchFree full text
  9. Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma.2024BMC cancerFree full text
  10. Tumor burden score is superior to primary liver cancer stages in predicting prognosis for patients with combined hepatocellular-cholangiocarcinoma after surgery: A multi-center study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  11. CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges.2024Frontiers in immunologyFree full text
  12. Single-cell profiling reveals the metastasis-associated immune signature of hepatocellular carcinoma.2024Immunity, inflammation and diseaseFree full text
  13. Myofibroblast-derived extracellular vesicles facilitate cancer stemness of hepatocellular carcinoma via transferring ITGA5 to tumor cells.2024Molecular cancerFree full text
  14. Lung immune prognostic index‑based nomogram for recurrence of hepatocellular carcinoma after postoperative adjuvant TACE.2023Journal of cancer research and clinical oncologyFree full text
  15. The ALKBH5/SOX4 axis promotes liver cancer stem cell properties via activating the SHH signaling pathway.2023Journal of cancer research and clinical oncologyFree full text
  16. Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma.2023Journal of medical virology
  17. Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer.2023Journal of visualized experiments : JoVE
  18. Silencing of peroxiredoxin 2 suppresses proliferation and Wnt/β-catenin pathway, and induces senescence in hepatocellular carcinoma.2023Oncology researchFree full text
  19. Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation.2022Cancer investigation
All its trials on ClinicalTrials.gov, any status9
  1. TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCCCompletedNCT04518852Lead sponsorPhase 2Start 2020-09
  2. TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular CarcinomaRecruitingNCT06485466Lead (inferred)Phase 3Start 2024-08
  3. CMRA for US-guided-MWA of Liver TumorsStatus unknownNCT05990257Lead (inferred)N/AStart 2018-07
  4. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  5. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  6. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical ResectionRecruitingNCT06560827Study sitePhase 1Start 2023-10
  7. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  8. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  9. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 13 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 4420212022: 4420222023: 1120232024: 1120242025: 222025

5 hospitals in Chengdu for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07392892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Wuhan

  3. Recruiting
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06901531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  4. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  5. Recruiting
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06155383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryNutrition & recoveryImaging & AI
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine
Papers it led13
  1. Molecular evidence of a clonal relationship of synchronous/multifocal gastric-type lesions of the female genital tract.2026The Journal of pathology
  2. Development of mapping algorithms for gastric cancer: translating EORTC QLQ-C30 and QLQ-STO22 to EQ-5D-5L health utilities.2025Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationFree full text
  3. Disparities in overall survival of gastric cancer patients after radical gastrectomy: an age and rural-urban residence-based cohort study with propensity score matching analysis.2025Scientific reportsFree full text
  4. Comment on: Cachexia index for prognostication in surgical patients with locally advanced oesophageal or gastric cancer: multicentre cohort study.2024The British journal of surgeryFree full text
  5. SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  6. Enhanced Recovery After Surgery protocol for elderly gastric cancer patients: A prospective study for safety and efficacy.2022Asian journal of surgery
  7. Perioperative nutrition management for gastric cancer.2022Nutrition (Burbank, Los Angeles County, Calif.)
  8. Association of multiple tumor markers with newly diagnosed gastric cancer patients: a retrospective study.2022PeerJFree full text
  9. The Value of the C-Reactive Protein-to-Lymphocyte Ratio for Predicting Lymphovascular Invasion Based on Nutritional Status in Gastric Cancer.2022Technology in cancer research & treatmentFree full text
  10. Laparoscopic proximal gastrectomy with double-tract reconstruction for upper third gastric cancer.2021BMC surgeryFree full text
  11. Al18F-NOTA-FAPI-04 Outperforms 18F-FDG PET/CT in Identifying the Primary Lesion and Rare Metastases From Gastric Cancer.2021Clinical nuclear medicine
  12. Laparoscopic versus open transhiatal approach for adenocarcinoma of the esophagogastric junction: A systematic review and meta-analysis.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  13. Two updates on oesophagogastric junction adenocarcinoma from the fifth WHO classification: Alteration of definition and emphasis on HER2 test.2021Histology and histopathology
All its trials on ClinicalTrials.gov, any status23
  1. Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerRecruitingNCT07392892Study sitePhase 2/Phase 3Start 2026-05
  2. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  3. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Study sitePhase 3Start 2025-05
  4. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  5. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Study sitePhase 2Start 2023-11
  6. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Study sitePhase 1/Phase 2Start 2025-01
  7. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  8. Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric CancerActive, not recruitingNCT06693128Study sitePhase 2Start 2024-11
  9. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  10. Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East AsiaCompletedNCT05606094Study siteStart 2023-03
  11. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  12. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  13. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  14. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  15. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  16. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  17. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  18. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  19. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  20. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Study sitePhase 1Start 2020-02
  21. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  22. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  23. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Chengdu for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 3 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

6 hospitals in Chengdu for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led3
  1. An ultrasound based method for predicting the malignant potential of primary gastrointestinal stromal tumors preoperatively.2024Abdominal radiology (New York)
  2. Gastrointestinal stromal tumors regulate macrophage M2 polarization through the MIF/CXCR4 axis to immune escape.2024Frontiers in immunology
  3. SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
Earlier papers (2016–2020)1
  1. Splenosis with lower gastrointestinal bleeding mimicking colonical gastrointestinal stromal tumour.2017World journal of surgical oncology
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Chengdu for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

16 hospitals in Chengdu for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Tetrahedral DNA loaded siCCR2 restrains M1 macrophage polarization to ameliorate pulmonary fibrosis in chemoradiation-induced murine model.2024Molecular therapy : the journal of the American Society of Gene Therapy
Chinese-language papers (not in the count)1
  1. [Research and Application of Stem Cell-Based Therapy in Idiopathic Pulmonary Fibrosis: A Review].2021Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

四川省肿瘤医院

Sichuan Cancer Hospital

成都

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Sichuan Clinical Research Center for Cancer; Sichuan Cancer Hospital & Institute; Sichuan Cancer Hospital and Institute; Sichuan Cancer Research Center for Cancer; Sichuan Cancer Center; Sichuan Cancer Hospital and Research Institute; Sichuan Cancer Hospital and Institution; Sichuan Cancer Hospital & Institution

Suggest a correctionDownload the data